Anabolic-Androgenic Steroids

A Visual Forensic Guide to Ten Prevalent Compounds

Pharmacokinetics, detection science, clinical profile, and litigation use for attorneys, judges, and forensic professionals

By ToxGirl

The legal point: AAS cases are rarely won or lost on the label “steroid.” They turn on compound identity, detection window, confirmation method, dose/timeline fit, and whether the expert can distinguish exposure from impairment or recent use.

Introduction

Anabolic-androgenic steroids (AAS) occupy a uniquely difficult space in forensic toxicology. They are legitimate therapeutic agents in some contexts, regulated controlled substances in others, and common performance-enhancing drugs in athletics and general-population misuse.

For legal professionals, the science cannot be reduced to a positive/negative label. Testosterone is endogenous and requires isotope-ratio confirmation. Nandrolone can remain detectable long after use. Oral 17-alpha alkylated compounds create liver-risk questions distinct from injectable esters. Veterinary-only drugs such as trenbolone and boldenone raise a different forensic inference than FDA-approved medications.

This revised article converts the original compound-by-compound guide into a visual litigation reference: a fast comparison chart, detection-window graphics, a toxicological risk heat map, and a practical attorney checklist.

Key Takeaways for Legal Professionals

• All ten compounds discussed here are controlled AAS; the legal analysis still requires compound-specific toxicology rather than class-wide generalizations.
• Detection windows vary from roughly three weeks to 12-18 months, which makes timeline reconstruction central in any prosecution, sanction, employment action, or expert report.
• Anabolic and androgenic ratings are derived from bioassays and are not direct evidence of human impairment, intent, aggression, or behavioral change.
• Testosterone requires C-IRMS confirmation because it is endogenous; a T/E ratio alone is an investigative trigger, not a complete forensic conclusion.
• Trenbolone has no FDA-approved human use; any confirmed human detection is exogenous, but that still does not automatically prove timing, dose, or impairment.
• Oral 17-alpha alkylated compounds – especially oxymetholone, stanozolol, and methandrostenolone – raise hepatotoxicity issues that differ from most injectable esters.

Visual Summary: What Changes the Litigation Analysis?

Interpretation: The ratings are best used as a relative pharmacology screen. They should not be converted into courtroom claims of impairment, aggression, or recent use without compound-specific human data and case-specific facts.

Timeline warning: A long detection window can prove past exposure while saying little about when use occurred. Nandrolone is the classic example: detection can persist far beyond any alleged acute effect.

Risk map key: 0 = none, 1 = low/minimal, 2 = moderate, 3 = high/significant, 4 = severe/very high/extreme. Scores summarize the article’s qualitative categories and are intended as visual triage, not medical diagnosis.

Part I: The Science Beneath the Label

What “Anabolic-Androgenic” Means

Every compound in this guide acts primarily through the androgen receptor, a nuclear transcription factor present in muscle, bone, liver, brain, prostate, and other tissues. Binding can alter protein synthesis, nitrogen retention, erythropoiesis, bone density, and secondary sex-characteristic signaling.

“Anabolic” generally refers to tissue-building effects, especially skeletal muscle. “Androgenic” refers to masculinizing effects, including prostate activity, sebaceous gland effects, virilization, and hair-loss risk in susceptible individuals. The two effects cannot be fully separated because they proceed through the same receptor system.

Courtroom translation: A high anabolic:androgenic ratio does not equal proof of strength increase, aggression, intoxication, or impairment in a particular human being. It is a historical comparative measure, not a clinical verdict.

Structural Families That Matter

19-nor compounds: Nandrolone and trenbolone lack the C-19 methyl group. This changes metabolism and often increases progestogenic relevance. Both can strongly suppress the HPTA.

DHT-derived compounds: Stanozolol, oxandrolone, drostanolone, and methenolone are resistant to aromatization and have distinct androgenic profiles.

17-alpha alkylated oral compounds: Stanozolol oral, oxandrolone, oxymetholone, and methandrostenolone are orally bioavailable but carry hepatic-risk issues because the C-17 modification resists first-pass metabolism.

Testosterone-derived compounds: Boldenone is structurally close to testosterone, but the C-1,2 double bond and undecylenate ester alter aromatization, release, and metabolite interpretation.

The Ester System

Many injectable AAS are esterified at the C-17 hydroxyl group. After intramuscular injection, the ester acts as a depot. Lipases cleave the ester and release active steroid over days to weeks. Long-chain esters such as decanoate, undecylenate, and enanthate generally produce slower release and longer detection windows; short esters such as propionate and acetate peak and clear faster. This is why route, ester, dose, and chronicity are central to timeline analysis.

Part II: Compound Profiles – Litigation-Relevant Summary

Testosterone (Test)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
100	100	~12 wk	High	Low	Yes

Reference standard; endogenous; IRMS required

Forensic emphasis: because testosterone is endogenous, exogenous use requires C-IRMS confirmation. A T/E ratio is an investigative flag, not a stand-alone forensic conclusion.

Nandrolone Decanoate (Deca)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
125	37	12-18 mo	Low	Low	Yes

Longest detection window; 19-NA metabolite

Forensic emphasis: the extraordinarily long 19-norandrosterone detection window is powerful for exposure evidence but dangerous if misused as proof of recent use or current effect.

Boldenone Undecylenate (EQ)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
100	50	~22 wk	Low-Mod	Low	No

Veterinary compound; hematocrit/polycythemia issue

Forensic emphasis: do not treat this compound as interchangeable with testosterone or any other AAS. The ester, metabolite, and adverse-effect profile control the analysis.

Trenbolone (Tren)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
500	500	~22 wk	None	Low	No

No human indication; any detection is exogenous

Forensic emphasis: no FDA-approved human indication makes confirmed detection exogenous, but the expert must still address timing, dose, method, and behavioral relevance.

Stanozolol (Winny)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
320	30	~9 wk	None	High	Yes

Oral vs depot timelines differ; HDL/tendon risk

Forensic emphasis: the 17-alpha alkylated oral class creates hepatic and lipid-risk issues, but route and timing still require compound-specific proof.

Oxandrolone (Anavar)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
400	24	~5 wk	None	Mild	Yes

Safer oral AAS profile, still 17-AA

Forensic emphasis: the 17-alpha alkylated oral class creates hepatic and lipid-risk issues, but route and timing still require compound-specific proof.

Drostanolone (Mast)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
96	33	~12 wk	Anti-E	Low	No

DHT-derived; mild anti-estrogenic activity

Forensic emphasis: do not treat this compound as interchangeable with testosterone or any other AAS. The ester, metabolite, and adverse-effect profile control the analysis.

Methenolone (Primo)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
88	50	~6 wk	Minimal	Low	Yes

Low suppression and low hepatic burden

Forensic emphasis: do not treat this compound as interchangeable with testosterone or any other AAS. The ester, metabolite, and adverse-effect profile control the analysis.

Oxymetholone (Adrol)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
320	45	~8 wk	None*	Severe	Yes

Most hepatotoxic oral; paradoxical estrogenic effects

Forensic emphasis: the 17-alpha alkylated oral class creates hepatic and lipid-risk issues, but route and timing still require compound-specific proof.

Methandrostenolone (Dbol)

Anabolic	Androgenic	Max Detection	Aromatization	Hepatic Risk	FDA Approved
210	60	~6 wk	High	High	No

Classic oral AAS; hepatotoxic and estrogenic

Forensic emphasis: the 17-alpha alkylated oral class creates hepatic and lipid-risk issues, but route and timing still require compound-specific proof.

Part III: Side-by-Side Comparison Tables

Compound	Anabolic	Androgenic	Max Detection	Aromatizes	Progestogenic	Hepatotoxic	HPTA	Water	FDA
Test	100	100	12 wk	High	Low	Low	Significant	High	Yes
Deca	125	37	12-18 mo	Low	High	Low	Severe	Moderate	Yes
EQ	100	50	22 wk	Low-Mod	None	Low	Moderate	Low	No
Tren	500	500	22 wk	None	Very High	Low	Extreme	Low	No
Winny	320	30	9 wk	None	None	High	Moderate	None	Yes
Anavar	400	24	5 wk	None	None	Mild	Mild-Mod	Low	Yes
Mast	96	33	12 wk	Anti-E	None	Low	Moderate	None	No
Primo	88	50	6 wk	Minimal	Low	Low	Mild	Low	Yes
Adrol	320	45	8 wk	None*	None*	Severe	Severe	Extreme	Yes
Dbol	210	60	6 wk	High	Low	High	Mod-Sev	High	No

* Anadrol: no aromatization, but estrogenic/gynecomastia effects are reported through an unclear mechanism. Ratings and detection windows are approximate and depend on dose, chronicity, method sensitivity, matrix, and individual pharmacokinetics.

Part IV: Forensic Detection Science

The Testing Stack

• Immunoassay screening: Fast and inexpensive, but prone to cross-reactivity. It is a screen only.
• GC-MS/MS: Core confirmation method for many AAS and metabolites; provides structural fragmentation data.
• LC-MS/MS: Preferred for polar, thermolabile, and some high-molecular-weight metabolites; important in modern anti-doping protocols.
• C-IRMS: Required when the question is whether testosterone or related endogenous steroids are synthetic/exogenous.

The admissibility problem: A laboratory summary that says “positive” without showing screening method, confirmatory method, metabolite identity, threshold, uncertainty, and chain of custody is not a scientifically complete forensic report.

Chain of Custody and Collection Questions

• Was the collection observed, and was specimen substitution reasonably excluded?
• Was temperature measured immediately at collection, and was it within physiological range?
• Were creatinine and specific gravity consistent with an authentic, non-dilute specimen?
• Was a split sample preserved, and can a B sample be tested?
• Was the laboratory properly accredited for the purpose asserted?
• Was the reported metabolite specific to the compound, or merely a class-level inference?

Common Defense Challenges in AAS Cases

Issue	Why It Matters	Attorney/Expert Move
Supplement contamination	Some AAS positives can arise from contaminated over-the-counter products or precursors.	Demand quantitative levels, supplement history, lot testing, and literature-consistent contamination analysis.
Endogenous steroids	Testosterone and trace nandrolone issues can be endogenous or confounded.	Require IRMS or compound-specific metabolite confirmation before accepting exogenous-use opinions.
Detection window overreach	A positive result may reflect past exposure outside the relevant event window.	Compare the alleged timeline to ester, route, chronicity, dose, metabolite, and matrix.
Screening-only evidence	Immunoassay screens are not legally or scientifically equivalent to confirmation.	Demand chromatograms, method validation, uncertainty, calibration, and chain-of-custody documents.
Clinical leapfrogging	Presence is not impairment, aggression, intent, or causation.	Force the expert to identify human evidence connecting the compound, dose, timing, and behavior at issue.

Conclusion

The forensic toxicology of anabolic-androgenic steroids is not a monolith. These ten compounds differ materially in structure, ester release, metabolite profile, detection window, hormonal activity, adverse-effect profile, and legal significance.

The central courtroom principles are consistent: screening is not confirmation; detection is not recent use; potency ratings are not impairment proof; testosterone requires isotope-ratio work; and long detection windows can be as exculpatory as they are incriminating when the alleged timeline does not fit the pharmacokinetics.

Attorney Checklist

• Obtain the full analytical packet, not only the summary result.
• Demand chain-of-custody documents from collection through analysis.
• Identify the exact compound and metabolite used for confirmation.
• For testosterone, confirm C-IRMS was performed; do not accept T/E ratio alone.
• Compare the alleged timeline with the compound’s ester, route, chronicity, and detection window.
• Review supplement contamination, endogenous production, and matrix-specific limitations.
• Attack any opinion that equates anabolic/androgenic ratings with impairment, aggression, or legal causation.

---

---